聚腺苷酸核糖聚合酶抑制治疗卵巢血管肉瘤：一例报告并文献复习
Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature.
作者信息
Johnson Andrea M, Argenta Peter A
机构信息
Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, United States.
Division Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN 55455, United States.
出版信息
Gynecol Oncol Rep. 2023 Aug 23;49:101264. doi: 10.1016/j.gore.2023.101264. eCollection 2023 Oct.
Abstract
•Primary angiosarcoma of the ovary historically has no standard treatment due to its rarity, and outcomes have been variable.•Olaparib may represent a viable treatment option for primary angiosarcoma of the ovary with a somatic BRCA mutation.•Next-generation sequencing may play an important component in treatment of very rare cancers to guide new or uncommon therapies.
摘要
•由于卵巢原发性血管肉瘤罕见，历史上一直没有标准治疗方法，治疗结果也各不相同。
•奥拉帕尼可能是治疗伴有体细胞BRCA突变的卵巢原发性血管肉瘤的一种可行治疗选择。
•新一代测序可能在极罕见癌症的治疗中发挥重要作用，以指导新的或不常见的治疗方法。
相似文献
1
Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature.聚腺苷酸核糖聚合酶抑制治疗卵巢血管肉瘤：一例报告并文献复习
Gynecol Oncol Rep. 2023 Aug 23;49:101264. doi: 10.1016/j.gore.2023.101264. eCollection 2023 Oct.
2
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.BRCA1/2 突变复发性卵巢癌行细胞减灭术后化疗联合奥拉帕利维持治疗：MITO 组回顾性研究。
Int J Gynecol Cancer. 2021 Jul;31(7):1031-1036. doi: 10.1136/ijgc-2020-002343. Epub 2021 May 14.
3
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.奥拉帕利一线维持单药治疗BRCA突变的上皮性卵巢癌：法国首个真实世界数据研究的描述性分析
Drugs Real World Outcomes. 2023 Jun;10(2):207-213. doi: 10.1007/s40801-022-00349-9. Epub 2023 Jan 11.
4
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.复发性卵巢癌奥拉帕利治疗期间患者咨询及症状管理
Oncologist. 2016 Aug;21(8):954-63. doi: 10.1634/theoncologist.2015-0268. Epub 2016 Jun 2.
5
The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.PARP 抑制剂奥拉帕利会耗尽小鼠的卵巢储备：对生育力保存的影响。
Hum Reprod. 2020 Aug 1;35(8):1864-1874. doi: 10.1093/humrep/deaa128.
6
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.奥拉帕利对比二次细胞减灭术后铂类化疗在复发性卵巢癌患者中的疗效：III 期随机、开放标签 MITO 35b 研究，MITO-MANGO 研究组项目。
Int J Gynecol Cancer. 2022 Jun 6;32(6):799-803. doi: 10.1136/ijgc-2022-003435.
7
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.奥拉帕利维持治疗新诊断的 BRCA 突变晚期卵巢癌患者（SOLO1/GOG 3004）：一项随机、双盲、安慰剂对照、III 期临床试验的 5 年随访。
Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26.
8
Pediatric Primary Ovarian Angiosarcoma: From Rarity to a Realization.小儿原发性卵巢血管肉瘤：从罕见病到被认知
J Pediatr Adolesc Gynecol. 2018 Dec;31(6):629-631. doi: 10.1016/j.jpag.2018.08.008. Epub 2018 Sep 1.
9
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.BRCA1/2 种系和体细胞突变景观在高级别浆液性卵巢癌患者中的分析。
BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
10
GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.GEICO1601 - 罗兰多：一项多中心单臂II期临床试验，旨在评估奥拉帕利与聚乙二醇化脂质体阿霉素联合用于铂耐药卵巢癌的疗效。
Future Sci OA. 2019 Jan 10;5(2):FSO370. doi: 10.4155/fsoa-2018-0107. eCollection 2019 Feb.
引用本文的文献
1
Atypical Pelvic Tumors in Children.儿童非典型盆腔肿瘤
Cancers (Basel). 2025 Feb 12;17(4):619. doi: 10.3390/cancers17040619.
2
Ovarian Angiosarcoma With Intractable Intraperitoneal Hemorrhage: A Case Report and Review of the Literature.伴有顽固性腹腔内出血的卵巢血管肉瘤：一例报告并文献复习
Cureus. 2025 Jan 3;17(1):e76849. doi: 10.7759/cureus.76849. eCollection 2025 Jan.
3
Primary Ovarian Angiosarcoma: Diagnostic Challenges and Conundrums.原发性卵巢血管肉瘤：诊断挑战与难题
Discoveries (Craiova). 2024 Dec 31;12(4):e198. doi: 10.15190/d.2024.17. eCollection 2024 Oct-Dec.
本文引用的文献
1
Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.葡萄牙临床实践中肺癌、罕见肿瘤及原发灶不明癌症的下一代测序共识建议。
Acta Med Port. 2022 Sep 1;35(9):677-690. doi: 10.20344/amp.17680. Epub 2022 Jul 11.
2
Ovarian epithelioid angiosarcoma complicating pregnancy: a case report and review of the literature.卵巢上皮样血管肉瘤合并妊娠：病例报告及文献复习。
J Int Med Res. 2021 May;49(5):3000605211019641. doi: 10.1177/03000605211019641.
3
Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor.原发性卵巢血管肉瘤：一种罕见且可识别的卵巢肿瘤。
J Ovarian Res. 2021 Jan 28;14(1):21. doi: 10.1186/s13048-021-00771-7.
4
Pediatric ovarian angiosarcoma treated with systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy: Case report and review of therapy.儿童卵巢血管肉瘤采用全身化疗和细胞减灭术联合腹腔内热化疗治疗：病例报告及治疗回顾。
Pediatr Blood Cancer. 2019 Jul;66(7):e27753. doi: 10.1002/pbc.27753. Epub 2019 Apr 11.
5
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.曲贝替定联合奥拉帕利治疗不可切除的晚期骨和软组织肉瘤患者（TOMAS）：一项来自意大利肉瘤研究组的开放标签、1b 期研究
Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.
6
Pediatric Primary Ovarian Angiosarcoma: From Rarity to a Realization.小儿原发性卵巢血管肉瘤：从罕见病到被认知
J Pediatr Adolesc Gynecol. 2018 Dec;31(6):629-631. doi: 10.1016/j.jpag.2018.08.008. Epub 2018 Sep 1.
7
Primary ovarian angiosarcoma in a 12- year -old girl: a case report of an exceptional localization in a context of limited resources country.一名12岁女孩的原发性卵巢血管肉瘤：资源有限国家中一例罕见部位的病例报告
BMC Clin Pathol. 2017 Aug 24;17:16. doi: 10.1186/s12907-017-0056-x. eCollection 2017.
8
Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification.基于吉西他滨的方案治疗伴有MYC扩增的原发性卵巢血管肉瘤
Curr Oncol. 2014 Dec;21(6):e782-9. doi: 10.3747/co.21.2144.
9
Complete response after MAID treatment for advanced primary ovarian angiosarcoma: case report and literature review.晚期原发性卵巢血管肉瘤经MAID治疗后的完全缓解：病例报告及文献综述
Eur J Gynaecol Oncol. 2014;35(3):318-21.
10
Ovarian angiosarcoma: Extended survival following optimal cytoreductive surgery and adjuvant chemotherapy.卵巢血管肉瘤：最佳肿瘤细胞减灭术及辅助化疗后的生存期延长
Gynecol Oncol Case Rep. 2012 Dec 20;4:23-5. doi: 10.1016/j.gynor.2012.12.006. eCollection 2012.
Zotero 插件